| Literature DB >> 25887225 |
Libo He1, Yongyan Pei2,3, Yao Jiang4,5, Yongming Li6, Lanjie Liao7, Zuoyan Zhu8, Yaping Wang9.
Abstract
BACKGROUND: Compensatory growth is accelerated compared with normal growth and occurs when growth-limiting conditions are overcome. Most animals, especially fish, are capable of compensatory growth, but the mechanisms remain unclear. Further investigation of the mechanism of compensatory growth in fish is needed to improve feeding efficiency, reduce cost, and explore growth-related genes.Entities:
Mesh:
Year: 2015 PMID: 25887225 PMCID: PMC4374334 DOI: 10.1186/s12864-015-1427-2
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Growth curve and SGR of grass carp during compensatory growth. (A) Growth curve of grass carp during compensatory growth. Fish in experimental and control groups were weighted at six time points and the weights were subjected to curve drawn. In each time point, 15 grass carp from three subgroups were random selected and weighted. Data are given as mean ± standard deviation (S.D.). (B) SGR of grass carp during compensatory growth. SGRs were calculated for control and experimental group during the three time intervals: 0 ~ 1 weeks, 1 ~ 2 weeks, and 2 ~ 5 weeks. Asterisks represent significant differences between groups at each time intervals (P < 0.01) that calculated by T test.
Summary of sequencing data and mapped results in the study
|
|
|
|
|
|
|
|
| ||
|---|---|---|---|---|---|---|---|---|---|
| (%) | Total | ||||||||
| mapped | |||||||||
| reads | Uniquely | ||||||||
| mapped | |||||||||
| reads | |||||||||
| After | |||||||||
| fasting | control group | muscle | C-1-M | a | 15314862 | 15128756 | 97.33 | 14059595 (92.93%) | 13217716 (87.37%) |
| b | 14823783 | 14646957 | 97.41 | 13619629 (92.99%) | 12843759 (87.69%) | ||||
| c | 16321214 | 16109369 | 97.33 | 14958284 (92.85%) | 14160730 | ||||
| (87.9%) | |||||||||
| liver | C-1-L | a | 14438249 | 14251753 | 96.49 | 13182134 (92.49%) | 12514167 (87.81%) | ||
| b | 17127547 | 16903996 | 96.56 | 15592380 (92.24%) | 14753416 (87.28%) | ||||
| c | 14523380 | 14310106 | 96.5 | 13233306 (92.48%) | 12636047 | ||||
| (88.3%) | |||||||||
| experimental group | muscle | E-1-M | a | 14988606 | 14778249 | 96.82 | 13616046 (92.14%) | 13093152 | |
| (88.6%) | |||||||||
| b | 17791102 | 17541598 | 96.93 | 16214273 (92.43%) | 15661812 (89.28%) | ||||
| c | 14762762 | 14589546 | 96.98 | 13498507 (92.52%) | 12890714 (88.36%) | ||||
| liver | E-1-L | a | 16289196 | 16107092 | 97.55 | 14933900 (92.72%) | 14405289 (89.43%) | ||
| b | 11491146 | 11345300 | 97.52 | 10536721 (92.87%) | 10183044 (89.76%) | ||||
| c | 17191329 | 16972319 | 97.38 | 15807590 (93.14%) | 15308206 | ||||
| (90.2%) | |||||||||
| After re-feeding | control group | muscle | C-2-M | a | 19323422 | 18945419 | 97.6 | 17275859 (91.19%) | 16426146 |
| (86.7%) | |||||||||
| b | 17903385 | 17565549 | 97.62 | 15988557 (91.02%) | 15240472 (86.76%) | ||||
| c | 21096997 | 20647765 | 97.63 | 18828972 (91.19%) | 17985183 | ||||
| (87.1%) | |||||||||
| liver | C-2-L | a | 17502755 | 17349119 | 97.56 | 16078785 (92.68%) | 15316916 (88.29%) | ||
| b | 17230237 | 17050272 | 97.52 | 15895193 (93.23%) | 15188285 (89.08%) | ||||
| c | 16617660 | 16399951 | 97.5 | 15177704 (92.55%) | 14472205 (88.25%) | ||||
| experimental group | muscle | E-2-M | a | 12796800 | 12303323 | 95.99 | 11089012 (90.13%) | 10562927 (85.85%) | |
| b | 20644903 | 19733726 | 95.82 | 17856999 (90.49%) | 17012127 (86.21%) | ||||
| c | 16427709 | 15639982 | 95.88 | 14047696 (89.82%) | 13295885 (85.01%) | ||||
| liver | E-2-L | a | 13892743 | 13713405 | 97.42 | 12794265 (93.3%) | 12273895 | ||
| (89.5%) | |||||||||
| b | 17895233 | 17661014 | 97.42 | 16454496 (93.17%) | 15843241 (89.71%) | ||||
| c | 15687125 | 15496141 | 97.43 | 14440618 (93.19%) | 13845040 (89.35%) |
Summary of DEGs in different comparison
|
|
|
|
| ||
|---|---|---|---|---|---|
|
|
|
| |||
| After | muscle | E-1-M/C-1-M | 2124 | 1937 | 4061 |
| fasting | liver | E-1-L/C-1-L | 761 | 1227 | 1988 |
| After re-feeding | muscle | E-2-M/C-2-M | 281 | 68 | 349 |
| liver | E-2-L/C-2-L | 148 | 99 | 247 | |
| Experimental group | muscle | E-2-M/E-1-M | 2668 | 2235 | 4903 |
| liver | E-2-L/E-1-L | 1512 | 932 | 2444 | |
Figure 2Venn diagram of DEGs between different comparisons. Overlapping regions represent DEGs in both comparisons. The size of the circle was made proportional to the number it represents. (A) Venn diagram of DEGs between E-1-M/C-1-M and E-1-L/C-1-L. (B) Venn diagram of DEGs between E-2-M/C-2-M and E-2-L/C-2-L. (C) Venn diagram of DEGs between E-2-M/E-1-M and E-2-L/E-1-L.
Figure 3Gene ontology of the top 30 enriched terms in different comparisons. Annotated genes were placed in three main categories, namely biological process, molecular function, and cellular component. The number of genes in each comparison is shown. A, E-1-M/C-1-M; B, E-1-L/C-1-L; C, E-2-M/C-2-M; D, E-2-L/C-2-L; E, E-2-M/E-1-M; F, E-2-L/E-1-L.
KEGG pathways of DEGs in different comparisons
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Metabolic pathways | 331 | 242 | 372 | 284 | ||
| Carbon metabolism | 51 | 30 | 10 | 8 | 50 | 36 |
| Fatty acid metabolism | 26 | 17 | 26 | 18 | ||
| Glycine, serine and threonine metabolism | 24 | 17 | 5 | 30 | 20 | |
| Citrate cycle (TCA cycle) | 22 | 11 | 48 | 18 | ||
| Biosynthesis of amino acids | 37 | 22 | 9 | 43 | 24 | |
| Glyoxylate and dicarboxylate metabolism | 15 | 16 | 11 | |||
| Glycolysis/Gluconeogenesis | 26 | 18 | ||||
| Biosynthesis of unsaturated fatty acids | 11 | 9 | 9 | |||
| Steroid biosynthesis | 10 | 13 | 13 | |||
| Terpenoid backbone biosynthesis | 11 | 11 | 4 | 12 | ||
| Selenocompound metabolism | 8 | 9 | 9 | 8 | ||
| 2-Oxocarboxylic acid metabolism | 10 | 13 | ||||
| Fructose and mannose metabolism | 18 | |||||
| Cysteine and methionine metabolism | 16 | 13 | 6 | 23 | ||
| Amino sugar and nucleotide sugar metabolism | 21 | 21 | ||||
| N-Glycan biosynthesis | 17 | 17 | ||||
| Glycerophospholipid metabolism | 23 | 26 | ||||
| Arginine and proline metabolism | 18 | 30 | 21 | |||
| Starch and sucrose metabolism | 13 | 14 | ||||
| Pyruvate metabolism | 13 | 22 | 14 | |||
| Pentose phosphate pathway | 10 | |||||
| One carbon pool by folate | 9 | 7 | 11 | 7 | ||
| Porphyrin and chlorophyll metabolism | 7 | 12 | ||||
| Pyrimidine metabolism | 9 | 47 | ||||
| Propanoate metabolism | 19 | |||||
| Phenylalanine metabolism | 7 | |||||
| Ubiquinone and other terpenoid-quinone biosynthesis | 5 | |||||
| Valine, leucine and isoleucine degradation | 22 | |||||
| Protein processing in endoplasmic reticulum | 53 | 41 | 67 | 56 | ||
| DNA replication | 20 | 6 | 31 | 13 | ||
| Proteasome | 22 | 19 | 22 | |||
| Aminoacyl-tRNA biosynthesis | 20 | 7 | 7 | 22 | ||
| Ribosome biogenesis in eukaryotes | 12 | 7 | 36 | |||
| RNA transport | 68 | |||||
| Mismatch repair | 16 | |||||
| Spliceosome | 55 | |||||
| Protein export | 14 | |||||
| Nucleotide excision repair | 23 | |||||
| Homologous recombination | 15 | |||||
| Base excision repair | 16 | |||||
| ECM-receptor interaction | 33 | 36 | ||||
| Cell cycle | 47 | 58 | 33 | |||
| Peroxisome | 23 |
Significant DEGs between experimental group and control group after fasting and re-feeding
|
|
|
|
|
|
|---|---|---|---|---|
| Fasting | up | Muscle E-1-M/C-1-M | Calcium-binding and coiled-coil domain-containing protein 1 ( | 7.47 |
| Kelch-like protein 38 ( | 6.67 | |||
| Methyltransferase-like protein 21C ( | 6.49 | |||
| F-box only protein 32 ( | 6.09 | |||
| SPRY domain-containing SOCS box protein 3 ( | 5.99 | |||
| Liver E-1-L/C-1-L | Hepcidin-1 | 8.39 | ||
| Nociceptin receptor | 5.98 | |||
| Insulin-like growth factor-binding protein 1 ( | 5.73 | |||
| Insulin-like growth factor-binding protein 4 ( | 5.64 | |||
| Krueppel-like factor 9 ( | 5.60 | |||
| down | Muscle E-1-M/C-1-M | Group 3 secretory phospholipase A2 ( | −8.10 | |
| Glucokinase | −7.10 | |||
| fatty acid binding protein 6 ( | −7.08 | |||
| Elongation of very long chain fatty acids protein-4 ( | −5.59 | |||
| Apolipoprotein A-I | −5.27 | |||
| Liver E-1-L/C-1-L | Glucokinase | −8.15 | ||
| Type-4 ice-structuring protein ( | −7.31 | |||
| Long-chain-fatty-acid--CoA ligase 1 ( | −7.21 | |||
| Major facilitator superfamily domain-containing protein 2A ( | −7.14 | |||
| Group 3 secretory phospholipase A2 ( | −7.10 | |||
| Re-feeding | up | Muscle E-2-M/C-2-M | Myosin heavy chain, fast skeletal muscle ( | 3.39 |
| Myosin heavy chain, fast skeletal muscle ( | 3.37 | |||
| Myosin heavy chain, fast skeletal muscle ( | 3.12 | |||
| Myosin-13 | 3.10 | |||
| Myosin heavy chain, fast skeletal muscle ( | 3.05 | |||
| Liver E-2-L/C-2-L | Parvalbumin beta | 5.73 | ||
| Myosin light chain 3, skeletal muscle isoform ( | 5.43 | |||
| Troponin C, skeletal muscle | 5.34 | |||
| Myosin regulatory light chain 2, skeletal muscle isoform ( | 5.27 | |||
| Parvalbumin-2 | 5.26 | |||
| down | Muscle E-2-M/C-2-M | Lovastatin nonaketide synthase | −2.53 | |
| Kelch domain-containing protein 1 ( | −1.97 | |||
| Ankyrin repeat domain-containing protein 29 ( | −1.47 | |||
| Kyphoscoliosis peptidase | −1.41 | |||
| Ankyrin repeat and SOCS box protein 2 ( | −1.38 | |||
| Liver E-2-L/C-2-L | Cytosolic phospholipase A2 gamma ( | −3.17 | ||
| Growth/differentiation factor 15 ( | −2.99 | |||
| Ankyrin repeat domain-containing protein 37 ( | −2.77 | |||
| Nuclear receptor coactivator 7 ( | −2.70 | |||
| Ferritin, middle subunit | −2.63 |
Significant DEGs in experimental group between fasting and re-feeding
|
|
|
|
|
|
|---|---|---|---|---|
| experimental group between fasting and re-feeding | up | MuscleE-2-M/E-1-M | Group 3 secretory phospholipase A2 ( | 6.13 |
| Actin, alpha skeletal muscle 2 ( | 5.85 | |||
| Elongation of very long chain fatty acids protein 4 ( | 5.68 | |||
| Glycine amidinotransferase, mitochondrial ( | 5.41 | |||
| Myosin heavy chain, fast skeletal muscle ( | 5.04 | |||
| Liver E-2-L/E-1-L | Type-4 ice-structuring protein ( | 7.75 | ||
| Elongation of very long chain fatty acids protein 6 ( | 7.20 | |||
| Long-chain-fatty-acid--CoA ligase 1 ( | 7.08 | |||
| Zinc finger FYVE domain-containing protein 9 ( | 7.01 | |||
| Group 3 secretory phospholipase A2 ( | 6.95 | |||
| down | Muscle E-2-M/E-1-M | Calcium-binding and coiled-coil domain-containing protein 1 ( | −7.82 | |
| Alpha-2-HS-glycoprotein ( | −6.45 | |||
| Protein-glutamine gamma-glutamyltransferase ( | −5.95 | |||
| SPRY domain-containing SOCS box protein 3 ( | −5.73 | |||
| Inactive dual specificity phosphatase 27 ( | −5.41 | |||
| Liver E-2-L/E-1-L | Calcium-independent phospholipase A2 ( | −7.50 | ||
| Heme oxygenase ( | −6.60 | |||
| Solute carrier organic anion transporter family member 1C1 ( | −6.32 | |||
| Solute carrier family 13 member 2 ( | −6.21 | |||
| Suppressor of cytokine signaling 2 ( | −5.71 |
Figure 4Validation of DEGs by qPCR. Twelve DEGs were random selected for qPCR analysis and compared with the equivalent RNA-seq data. The data from qPCR were presented as mean ± standard deviation of three replicates. The data from RNA-seq were the read counts that normalized by DEseq from three replicates. A and B, Expression level of MIF and PRDX3 in comparison E-1-M/C-1-M (grey bars, C-1-M; black bars, E-1-M); C and D, APOEb and EF-1α in comparison E-1-L/C-1-L (grey bars, C-1-L; black bars, E-1-L); E and F, APOA-I-1 and PAIP2B in comparison E-2-M/C-2-M (grey bars, C-2-M; black bars, E-2-M); G and H, PSD2 and ALDOb in E-2-L/C-2-L (grey bars, C-2-L; black bars, E-2-L); I and J, ALDOa and CFD in E-2-M/E-1-M (grey bars, E-1-M; black bars, E-2-M); K and L, EFF1α1L2 and GAPDH in E-2-L/E-1-L (grey bars, E-1-L; black bars, E-2-L).